Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

286 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles.
Gillespie SH, DiNardo AR, Georghiou SB, Sabiiti W, Kohli M, Panzner U, Kontsevaya I, Hittel N, Stuyver LJ, Tan JB, van Crevel R, Lange C, Thuong TNT, Heyckendorf J, Ruhwald M, Heinrich N. Gillespie SH, et al. Lancet Microbe. 2024 Sep;5(9):100869. doi: 10.1016/S2666-5247(24)00085-5. Epub 2024 May 9. Lancet Microbe. 2024. PMID: 38735303 Free article. Review.
Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment.
Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, Phillips PP, Venter A, Bateson A, Boehme CC, Heinrich N, Hunt RD, Boeree MJ, Zumla A, McHugh TD, Gillespie SH, Diacon AH, Hoelscher M; Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics (PanACEA). Friedrich SO, et al. Among authors: gillespie sh. Lancet Respir Med. 2013 Aug;1(6):462-70. doi: 10.1016/S2213-2600(13)70119-X. Epub 2013 Jul 1. Lancet Respir Med. 2013. PMID: 24429244 Free article. Clinical Trial.
Tuberculosis treatment monitoring tests during routine practice: study design guidance.
MacLean EL, Zimmer AJ, den Boon S, Gupta-Wright A, Cirillo DM, Cobelens F, Gillespie SH, Nahid P, Phillips PP, Ruhwald M, Denkinger CM. MacLean EL, et al. Among authors: gillespie sh. Clin Microbiol Infect. 2024 Apr;30(4):481-488. doi: 10.1016/j.cmi.2023.12.027. Epub 2024 Jan 3. Clin Microbiol Infect. 2024. PMID: 38182047 Free article.
Accuracy of the tuberculosis molecular bacterial load assay to diagnose and monitor response to anti-tuberculosis therapy: a longitudinal comparative study with standard-of-care smear microscopy, Xpert MTB/RIF Ultra, and culture in Uganda.
Musisi E, Wamutu S, Ssengooba W, Kasiinga S, Sessolo A, Sanyu I, Kaswabuli S, Zawedde J, Byanyima P, Kia P, Muwambi W, Toskin DT, Kigozi E, Walbaum N, Dombay E, Legrady MB, Ssemambo KD, Joloba M, Kuchaka D, Worodria W, Huang L, Gillespie SH, Sabiiti W. Musisi E, et al. Among authors: gillespie sh. Lancet Microbe. 2024 Apr;5(4):e345-e354. doi: 10.1016/S2666-5247(23)00367-1. Epub 2024 Mar 5. Lancet Microbe. 2024. PMID: 38458206 Free article.
Triage test for all-oral drug-resistant tuberculosis (DR-TB) regimen: a phase IV study to assess effectiveness, feasibility, acceptability and cost-effectiveness of the Xpert MTB/XDR assay for rapid triage and treatment of DR-TB.
Naidoo K, Naidoo A, Abimiku AG, Tiemersma EW, Gebhard A, Hermans SM, Sloan DJ, Ruhwald M, Georghiou SB, Okpokoro E, Agbaje A, Yae K, Tollera G, Moga S, Feyt H, Kachoka T, Letsoalo MP, Cabibbe AM, Perumal R, Shunmugam L, Cirillo DM, Foraida S, Sabiiti W, Ntinginya NE, Mtafya B, Bedru A, Gillespie SH; TRiAD Study Consortium. Naidoo K, et al. Among authors: gillespie sh. BMJ Open. 2024 Nov 27;14(11):e084722. doi: 10.1136/bmjopen-2024-084722. BMJ Open. 2024. PMID: 39609025 Free PMC article.
Protein binding of rifampicin is not saturated when using high-dose rifampicin.
Litjens CHC, Aarnoutse RE, van Ewijk-Beneken Kolmer EWJ, Svensson EM, Colbers A, Burger DM, Boeree MJ, Te Brake LHM; PanACEA-MAMS-TB-01 Team. Litjens CHC, et al. J Antimicrob Chemother. 2019 Apr 1;74(4):986-990. doi: 10.1093/jac/dky527. J Antimicrob Chemother. 2019. PMID: 30597025 Clinical Trial.
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
Cevik M, Thompson LC, Upton C, Rolla VC, Malahleha M, Mmbaga B, Ngubane N, Abu Bakar Z, Rassool M, Variava E, Dawson R, Staples S, Lalloo U, Louw C, Conradie F, Eristavi M, Samoilova A, Skornyakov SN, Ntinginya NE, Haraka F, Praygod G, Mayanja-Kizza H, Caoili J, Balanag V, Dalcolmo MP, McHugh T, Hunt R, Solanki P, Bateson A, Crook AM, Fabiane S, Timm J, Sun E, Spigelman M, Sloan DJ, Gillespie SH; SimpliciTB Consortium. Cevik M, et al. Among authors: gillespie sh. Lancet Infect Dis. 2024 Sep;24(9):1003-1014. doi: 10.1016/S1473-3099(24)00223-8. Epub 2024 May 17. Lancet Infect Dis. 2024. PMID: 38768617 Free article. Clinical Trial.
286 results